98 related articles for article (PubMed ID: 30870146)
1. Drug-Induced Liver Injury Due to Dulaglutide Use.
Patel AV; Jotwani PM; Lee TP
Am J Ther; 2019; 26(5):e620-e622. PubMed ID: 30870146
[No Abstract] [Full Text] [Related]
2. [Dulaglutide and liraglutide compared].
Bruhn C
Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
[No Abstract] [Full Text] [Related]
3. Pyoderma gangrenosum associated with dulaglutide therapy.
Hamann CR; Chung C; Kaffenberger BH
Int J Dermatol; 2019 Oct; 58(10):1202-1204. PubMed ID: 30345551
[No Abstract] [Full Text] [Related]
4. Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report.
Fukuda G; Yoshida T; Hirayama A; Umezawa Y; Takemoto M
Geriatr Gerontol Int; 2019 Dec; 19(12):1289-1290. PubMed ID: 31823494
[No Abstract] [Full Text] [Related]
5. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
[TBL] [Abstract][Full Text] [Related]
6. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
[TBL] [Abstract][Full Text] [Related]
7. Dulaglutide-induced cerebral venous thrombosis in a patient with type 2 diabetes mellitus.
Rajput R; Pathak V; Yadav PK; Mishra S
BMJ Case Rep; 2018 Nov; 2018():. PubMed ID: 30413453
[TBL] [Abstract][Full Text] [Related]
8. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
Yu M; Van Brunt K; Varnado OJ; Boye KS
Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
[TBL] [Abstract][Full Text] [Related]
12. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
Bajaj HS; Gerstein HC; Rao-Melacini P; Basile J; Colhoun H; Conget I; Cushman WC; Dagenais GR; Franek E; Hanefeld M; Keltai M; Lakshmanan M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Probstfield J; Raubenheimer P; Ryden L; Shaw JE; Sheu WH; Xavier D
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):484-490. PubMed ID: 34153269
[TBL] [Abstract][Full Text] [Related]
13. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
[TBL] [Abstract][Full Text] [Related]
14. New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
Hussar DA; Wetty DR
J Am Pharm Assoc (2003); 2015; 55(1):106, 108-10. PubMed ID: 25575154
[No Abstract] [Full Text] [Related]
15. Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.
Vinagre I; Gerstein H; Viñals C; Conget I
Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):467-468. PubMed ID: 30890422
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
[TBL] [Abstract][Full Text] [Related]
17. Dulaglutide for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
[TBL] [Abstract][Full Text] [Related]
18. Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.
Garg A; Kumar A
Curr Drug Saf; 2018; 13(3):165-170. PubMed ID: 29852875
[TBL] [Abstract][Full Text] [Related]
19. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
Umpierrez GE; Pantalone KM; Kwan AY; Zimmermann AG; Zhang N; Fernández Landó L
Diabetes Obes Metab; 2016 Jun; 18(6):615-22. PubMed ID: 26969812
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
Emoto M; Oura T; Matsui A; Kazama H; Iwamoto N
Endocr J; 2017 Feb; 64(2):191-206. PubMed ID: 27853058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
